VA
ORIC icon

VR Adviser’s Oric Pharmaceuticals ORIC Stock Holding History

VR Adviser’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.8M Hold
4,319,765
– – 1.42% 16
2026
Q1 		$54.7M Sell
4,319,765
-1,356,465
-24% -$15.4M 2.04% 13
2025
Q4 		$46.4M Sell
5,676,230
-920,655
-14% -$10.6M 2.29% 14
2025
Q3 		$79.2M Hold
6,596,885
– – 4.46% 8
2025
Q2 		$67M Buy
6,596,885
+3,414,358
+107% +$22.9M 5.02% 6
2025
Q1 		$17.8M Sell
3,182,527
-1,212,000
-28% -$10.6M 1.51% 17
2024
Q4 		$35.5M Hold
4,394,527
– – 2.43% 15
2024
Q3 		$45M Hold
4,394,527
– – 2.36% 15
2024
Q2 		$31.1M Hold
4,394,527
– – 1.98% 17
2024
Q1 		$60.4M Buy
4,394,527
+1,966,142
+81% +$23.4M 2.87% 13
2023
Q4 		$22.3M Buy
2,428,385
+285,529
+13% +$2.06M 1.53% 22
2023
Q3 		$13M Hold
2,142,856
– – 1.36% 23
2023
Q2 		$16.6M Buy
+2,142,856
New +$12.2M 2.66% 16

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIHC Capital Management Central $104M AUM

VR Adviser's ORIC Position: Q2 2026 in Review

VR Adviser held its Oric Pharmaceuticals (ORIC) position steady in Q2 2026 at 4,319,765 shares worth $46.8M. The position accounts for 1.42% of the portfolio, ranked #16.

VR Adviser first reported a position in ORIC in Q2 2023 and has held it in 13 quarters since. The position peaked at $79.2M in Q3 2025. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • VR Adviser held 4,319,765 shares of Oric Pharmaceuticals worth $46.8M as of Q2 2026.
  • VR Adviser left its Oric Pharmaceuticals share count unchanged in Q2 2026.
  • Oric Pharmaceuticals made up 1.42% of VR Adviser's portfolio in Q2 2026, its #16 holding.
  • VR Adviser first reported a position in Oric Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • VR Adviser's Oric Pharmaceuticals position peaked at $79.2M in Q3 2025.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.